{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Masi G"],"funding":["National Institute of Allergy and Infectious Diseases","National Institute of Neurological Disorders and Stroke","Takeda Pharmaceuticals U.S.A.","UCB Pharma","NCATS NIH HHS","Genentech","Centers for Disease Control and Prevention","NIAID NIH HHS","NINDS NIH HHS","National Institute of Mental Health","National Institutes of Health","Myasthenia Gravis Foundation of America"],"pagination":["577850"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9106915"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["367"],"pubmed_abstract":["Trial eligibility in myasthenia gravis (MG) remains largely dependent on a positive autoantibody serostatus. This significantly hinders seronegative MG (SNMG) patients from receiving potentially beneficial new treatments. In a subset of SNMG patients, acetylcholine receptor (AChR) autoantibodies are detectable by a clustered AChR cell-based assay (CBA). Of 99 SNMG patients from two academic U.S. centers, 18 (18.2%) tested positive by this assay. Autoantibody positivity was further validated in 17/18 patients. In a complementary experiment, circulating AChR-specific B cells were identified in a CBA-positive SNMG patient. These findings corroborate the clinical need for clustered AChR CBA testing when evaluating SNMG patients."],"journal":["Journal of neuroimmunology"],"pubmed_title":["The clinical need for clustered AChR cell-based assay testing of seronegative MG."],"pmcid":["PMC9106915"],"funding_grant_id":["R01 AI114780","R21 AI164590","R01-AI114780","R21-AI164590","UL1 TR001863","U54 NS115054","T32 AI007019"],"pubmed_authors":["Masi G","Nowak RJ","O'Connor KC","Pham MC","Li Y","Karatz T","Oxendine SR","Guptill JT"],"additional_accession":[]},"is_claimable":false,"name":"The clinical need for clustered AChR cell-based assay testing of seronegative MG.","description":"Trial eligibility in myasthenia gravis (MG) remains largely dependent on a positive autoantibody serostatus. This significantly hinders seronegative MG (SNMG) patients from receiving potentially beneficial new treatments. In a subset of SNMG patients, acetylcholine receptor (AChR) autoantibodies are detectable by a clustered AChR cell-based assay (CBA). Of 99 SNMG patients from two academic U.S. centers, 18 (18.2%) tested positive by this assay. Autoantibody positivity was further validated in 17/18 patients. In a complementary experiment, circulating AChR-specific B cells were identified in a CBA-positive SNMG patient. These findings corroborate the clinical need for clustered AChR CBA testing when evaluating SNMG patients.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2025-04-04T20:20:07.665Z","creation":"2025-02-19T02:17:31.268Z"},"accession":"S-EPMC9106915","cross_references":{"pubmed":["35366559"],"doi":["10.1016/j.jneuroim.2022.577850"]}}